Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

Historical Holders from Q2 2021 to Q3 2025

Symbol
VERV
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
89.6M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
104K
Holdings value
$1.24M
% of all portfolios
0%
Grand Portfolio weight change
-0.001%
Number of holders
5
Number of buys
1
Number of sells
-166
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Pentwater Capital Management LP 7.5% $74.8M 6.72M Pentwater Capital Management LP 30 Jun 2025
BlackRock, Inc. 7% $33.7M 6.18M BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 4.9% +6% $23.6M $2.23M 4.33M +10.4% Millennium Management LLC 22 Apr 2025
STATE STREET CORP 3.8% $17.7M 3.24M STATE STREET CORPORATION 31 Dec 2024

Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 104K $1.24M -$812M $11.23 5
2025 Q2 72.9M $819M +$44.4M $11.23 171
2025 Q1 80.8M $369M +$7.86M $4.57 189
2024 Q4 78.6M $444M +$18.4M $5.64 162
2024 Q3 75.3M $364M -$6.88M $4.84 169
2024 Q2 76.1M $371M -$40.9M $4.88 161
2024 Q1 81.6M $1.08B +$94.9M $13.28 160
2023 Q4 74.7M $1.04B +$151M $13.94 153
2023 Q3 63.9M $847M +$20.6M $13.26 129
2023 Q2 61.9M $1.16B -$19.8M $18.75 117
2023 Q1 63.3M $912M +$3.33M $14.42 122
2022 Q4 62.7M $1.21B +$9.17M $19.35 119
2022 Q3 60.7M $2.08B +$501M $34.35 120
2022 Q2 45.6M $696M -$28.5M $15.28 95
2022 Q1 46.6M $1.06B +$20.3M $22.82 91
2021 Q4 45.1M $1.66B +$125M $36.87 89
2021 Q3 38.7M $1.81B +$21.7M $47.00 72
2021 Q2 37.7M $2.25B +$2.25B $60.25 69